Global Remicade (infliximab) Drug Market Research Report 2022

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
Due to the COVID-19 pandemic, the global Remicade (infliximab) Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Remicade (infliximab) Drug market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Remicade (infliximab) Drug landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Brands Drugs accounting for % of the Remicade (infliximab) Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Crohn's Disease segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Remicade (infliximab) Drug include Janssen, Hospira, Celltrion Healthcare, Epirus Biopharmaceuticals and Samsung Bioepsis, etc. In terms of revenue, the global 3 largest players have a % market share of Remicade (infliximab) Drug in 2021.
This report focuses on Remicade (infliximab) Drug volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Remicade (infliximab) Drug market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Remicade (infliximab) Drug Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Brands Drugs
Generic Drugs
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Pediatric Ulcerative Colitis
Other
By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Janssen
Hospira
Celltrion Healthcare
Epirus Biopharmaceuticals
Samsung Bioepsis

Frequently Asked Questions